---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000181"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:26:56.881070+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunic closes $200M private placement; CEO Vitt to transition; Phase 3 MS data by end-2026

## Summary
- Closed oversubscribed private placement of up to $400M; $200M gross proceeds received Feb 17, 2026.
- Net proceeds ~$187M expected to fund operations into late 2027, including Phase 3 ENSURE trials and NDA submission mid-2027.
- CEO Daniel Vitt to transition to senior scientific role; search for new CEO with commercial MS expertise underway.
- Simona Skerjanec appointed Interim Chairperson; Thor Nagel (BVF Partners) named to Board.
- Net loss for FY2025 was $97.2M ($0.62/share); cash $15.5M at Dec 31, 2025, plus placement proceeds.

## SEC filing metadata
- accession: 0001193805-26-000181
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000181/0001193805-26-000181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000181/e665186_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000181
- JSON: https://secwatch.observer/filing/0001193805-26-000181.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.